Get rewarded for investing more into Evren Technologies, Inc:
Evren Technologies currently has a working prototype of the Phoenix® earbud and a beta version of the accompanying app
*Information based on internal research with resources provided by the National Center for PTSD ( source)
Millions are suffering from PTSD each year, but current treatments simply aren’t enough, leaving 66% of patients seeking better treatment options.
This is why we’re creating the Phoenix®, a non-invasive, affordable, and drug-free treatment for PTSD. The Phoenix is an innovative earbud device that will deliver personalized vagal nerve stimulation (VNS) to reduce PTSD severity and improve quality of life without the harmful side effects of prescription drugs. The pilot trial results were exceptional, earning the Phoenix Breakthrough Device Designation from the FDA. More importantly, PTSD patients loved the device. 100% of pilot trial participants wanted to keep their device after the trial, even those who achieved remission.
The device reduces PTSD severity, which includes symptoms such as depression, anxiety, insomnia, nightmares & flashbacks, social avoidance, and suicidality — and does so with no significant side effects. The Phoenix was recently awarded Breakthrough Device Designation by the FDA based on early clinical data, and we’re now ready to launch it into the next phase of development as we look to serve those chronically suffering from PTSD.
The Problem
Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. 15M Americans are impacted by PTSD in a typical year, and the pandemic has been far from typical, with rates soaring as high as 60M.
(source)
Despite millions of Americans dealing with PTSD on a daily basis, far too many patients are still looking for relief. The primary treatment option is antidepressants, which can cause increased suicidality and are intended only for short-term use.
Therapy, another common treatment in the patient roadmap, is more time and resource-intensive than many people can afford, and still lacks proper research, phenotyping, and individualization—oftentimes worsening symptoms. Researchers and academics agree that current therapies are inadequate, indicating a pressing need for new approaches to the issue.
The Solution
*The above rendering is a computer generated simulation.
The Phoenix will treat PTSD by stimulating the vagus nerve with a light electrical tingle, providing personalized dosing based on stress levels. It is completely non-invasive and has no significant adverse side effects. It's portable and discrete, allowing for treatment anywhere you need it. In short, it will empower users to take back control of their lives.
The result? PTSD patients love the Phoenix! 100% of users wanted to keep using the Phoenix after the pilot study and all of them were willing to pay out-of-pocket for it. Here is what they had to say:
*These testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
The Market
PTSD is an enormous global market, valued at $22.5B in the US alone.* The Phoenix is an extremely scalable technology at the forefront of 2 of the fastest growing medical device markets: Bioelectronic Medicine and Wearable Medical Devices.
*Information based on internal research done by Evren Technologies
Our Traction
Since Evren started in 2019, we’ve made great strides and have seen a phenomenal response from both PTSD patients and governing agencies.
This traction has allowed Evren to assemble an elite team of leading experts in PTSD, VNS, and military healthcare.
Why Invest
We envision a better future for those suffering from PTSD—though it doesn’t stop there. The Phoenix is an extremely scalable technology, with vagal nerve stimulation approved for the treatment of many other disorders, including epilepsy, opioid withdrawal, major depressive disorder, and migraines, with potential application for a longer list that includes anxiety, insomnia, long COVID and traumatic brain injury.
Join us on our mission to improve countless lives, enable a happier, healthier future, and empower patients to #RiseAbovePTSD.
*The above is a rendering of Evren's Phoenix earbud. Images feature a computer generated model. Product is still currently under development.
Company | : | Evren Technologies, Inc |
Corporate Address | : | 404 SW 140th Terrace, Suite 50, Gainesville, FL 32669 |
Offering Minimum | : | $9,994.95 |
Offering Maximum | : | $1,069,998.30 |
Minimum Investment Amount(per investor) | : | $399.00 |
Offering Type | : | Equity |
Security Name | : | Common Stock |
Minimum Number of Shares Offered | : | 1,503 |
Maximum Number of Shares Offered | : | 160,902 |
Price per Share | : | $6.65 |
Pre-Money Valuation | : | $15,085,870.80 |
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Time-Based
Friends and Family Early Birds
Invest within the first 72 hours and receive 15% bonus shares.
Early Bird Bonus
Invest within the first week (7 calendar days) and receive 10% bonus shares.
Amount-Based
Investor | $1,000+
Invest $1,000+ and receive 50% off device purchase (coupon for use once the product is available on the market).
Watt | $5,000+
Invest $5,000+ and receive 5% bonus shares + 50% off device purchase (coupon for use once the product is available on the market).
Franklin | $10,000+
Invest $10,000+ and receive 10% bonus shares + 50% off 2 device purchases (coupons for use once the product is available on the market).
Edison | $25,000+
Invest $25,000+ and receive 20% bonus shares + 50% off 3 device purchases (coupons for use once the product is available on the market).
Tesla | $50,000+
Invest $50,000+ and receive 25% bonus shares + 50% off 4 device purchases (coupons for use once the product is available on the market).
*All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Evren Technologies, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $6.65 / share, you will receive 110 shares Common Stock, meaning you'll own 110 shares for $665. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Insider Investment Notice
Officers, directors, executives, and existing owners with a controlling stake in the company (or their immediate family members) may make investments in this offering. Any such investments will be included in the raised amount reflected on the campaign page.
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.
Read this moving testimonial from one of our recent investors detailing why he decided to support Evren Technologies’s mission.
"I invested in Evren Technologies because I have suffered from Major Depressive Disorder for almost 23 years. I know there is a huge unmet need for better PTSD, depression, and anxiety treatments.
The technology that Evren has developed and manufactured is groundbreaking and exciting. First, to know that so many people could receive such a simple but effective treatment is encouraging, especially without needing health insurance. Secondly, the type of device that Evren has developed is convenient and side-effect free.
The unmet need for better PTSD treatment is huge. So many of our country’s military men and women are being affected mentally. After sacrificing their lives, families, and time, they deserve the best treatment options available.
With the onset of the pandemic in 2020, and the fallout that has occurred, mental illness is reaching all time high levels. More treatments like The Phoenix device need to be made readily available to ALL that need it, regardless of financial or health insurance status.
As someone who suffers from mental illness, I think it’s wonderful what Evren Technologies has developed for those suffering from PTSD. I would love to see Evren Technologies take treatment to a new level. I would also like to see Evren’s device indications expand, to treat depression, anxiety, personality disorders, schizophrenia, and all types of mental illness.
To me, it’s a privilege and pleasure, to be able to aid in furthering Evren Technologies’s research and development." - Thomas Warrington
Pilot study participants saw an average 18.4 pt reduction in CAPS-5. No wonder 100% of our participants wanted to keep The Phoenix earbud!
Visit our raise page on StartEngine to learn more about our mission to enable a happier, healthier future for people with PTSD.
Warmly,
Weaver Gaines
CEO
Evren Technologies
“This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.”
Are you on the fence about potentially investing or considering reinvesting in Evren Technologies? Tomorrow is your last chance to speak to CEO Weaver Gaines about exciting developments in Evren’s future.
Don’t miss our live Q&A investor webinar on August 16th at 4:00 pm EDT! There is only 1 day left to register!
PTSD is an underserved $22.5B market which leaves 66% of patients still seeking relief through new treatment solutions. Evren Technologies was recently awarded a Breakthrough Device Designation by the FDA for demonstrating the Phoenix can better alleviate symptoms than current available therapies with no side effects.
15 million adults in the U.S. suffer from PTSD every year, and by investing in Evren Technologies, you can contribute to making a real difference in their lives.
Sign up today for one final, farewell webinar with the Evren Team before our campaign closes.
Remember to share our raise page with your network so they can learn more about investment opportunities!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Time is becoming increasingly limited to invest in our StartEngine campaign.
There are only 2 weeks left to get in on the ground floor of the company developing the revolutionary Phoenix earbud - an all in one system designed to alleviate the symptoms of PTSD. .
PTSD is an underserved, $22.5 Billion-dollar market with 66% of those suffering currently seeking new treatment solutions. 15 Million Americans will suffer from PTSD in any given year, and over 60 million had PTSD during the height of the COVID shutdown.
Now is the time to invest in a revolutionary treatment designed to combat PTSD symptoms - with no side effects. 100% of trial participants wanted to keep the device!
We envision a better future for people suffering from PTSD, and with the growing support of investors like you, we can make this dream a reality.
Learn more about joining our investor community by visiting our raise page today. Please help spread the word by sharing with your friends, family, and network!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Hello Evren Community!
Don’t miss your last chance to chat with Evren’s CEO, Weaver Gaines! He is hosting a final investor Q&A webinar before our StartEngine campaign ends.
There are only 3 days left to register!
Reserve your spot today to chat with the Evren team on August 16th at 4:00pm EDT.
With the continuous support of our growing inverter community, Evren Technologies is primed to take on the next stages of research and development for our revolutionary technologies.
Evren’s Phoenix earbud has been shown to alleviate symptoms of PTSD without adverse side effects, greatly improving patients’ quality of life.
Together with investors like you, we are helping people rise above PTSD by alleviating debilitating symptoms.
Please share this amazing opportunity with your friends, family, and network.
Warmly,
Weaver Gaines
CEO
Evren Technologies
Millions of Americans suffer from the debilitating symptoms that come from surviving trauma. PTSD affects everyone differently, but many experience extreme anxiety, depression, anger, social isolation, insomnia, and suicidality. Symptoms can interfere with someone’s interpersonal relationships and even prevent them from being able to work. Living with panic and flashbacks can leave a person too exhausted to conduct their daily lives.
Unfortunately, most of the current treatments available don’t do enough to eliminate symptoms of PTSD. Over 66% of patients who begin therapy are still seeking relief from their most persistent symptoms.
In our clinical trials, an astounding 100% of participants experienced reduced symptoms and wanted to keep the device! Overall, participants experienced up to a 91% decrease in symptoms.
Recently, the Phoenix was awarded a Breakthrough Device Designation by the FDA, which will help us fast track our trials. Evren Technologies is dedicated to helping alleviate symptoms of PTSD for millions of people. We continue to further research in this developing field and develop new technologies to help people rise above PTSD.
PTSD treatment is a $22.5B market that continues to grow every year. You can help us provide relief to those who need it most by investing in Evren Technologies for as little as $399.
With the help of our growing investor community, we can alleviate the suffering of people with PTSD everywhere.
Visit our raise page on StartEngine today to learn more about the benefits of investing in Evren Technologies. Please share with your friends, family, and network!
Warmly,
Weaver Gaines
CEO
Evren Technologies
Check out this recent article on Vagal Nerve Stimulation (VNS) in the New York Times! Read about how this revolutionary technology is changing lives. Evren Technologies was featured in the New York Times in June.
Our wellbeing is dependent on a functional and adaptive nervous system. PTSD leads to a maladaptive system, which makes people feel unsafe all the time. The key to regulating the safety response is the vagus nerve, which basically controls the safety response.
The Phoenix delivers stimulation to the auricular branch of the vagus nerve through the ear, bringing it back into balance. This allows PTSD victims to finally feel safe again.
The continued coverage of VNS by major publications is a testament to the rapid growth of the field. This is your chance to get in at the ground floor by investing in Evren, one of the top biotech campaigns on StarEngine!
Join our mission to create a brighter future for those struggling with debilitating symptoms. Visit our raise page on StartEngine to learn about the perks of early investment. Please share this great opportunity with your family, friends, and network.
Together, we can ease suffering and help people rise above PTSD!
Warmly,
Weaver Gaines
CEO
Evren Technologies
There are only 5 days left until CEO Weaver Gaines hosts his final webinar. Join us and learn about why our Phoenix earbud was awarded an FDA Breakthrough Device Designation and what this means for the future of Evren Technologies.
With 100% of trial participants wanting to keep the device after the studies ended, this revolutionary device is primed to significantly improve the lives of people suffering from PTSD.
Register today for our live webinar on August 16th at 4:00pm EDT to reserve your spot.
This is your last chance to personally ask your investor questions before our StartEngine campaign ends.
We invite you to share our webinar with your friends, family, and network.
Warmly,
Weaver Gaines
CEO
Evren Technologies
There are many great reasons to join the Evren team, as seen by our steadily growing investor community. Here’s a recent testimonial from one of our investors explaining what convinced her to support Evren Technologies’s mission to help people rise above PTSD.
“I invested because those with PTSD need a better option. In my opinion, The Phoenix® earbud is that option. Society needs to move away from prescription drugs. This technology could give the PTSD community a drug free option that truly works. Thank you to the entire Evren Team for dedicating their time and efforts to such a great cause.” - Susan Hughes, Investor
PTSD is an underserved $22.5B market in the U.S. alone, affecting over 15 million people. The Phoenix® earbud uses vagus nerve stimulation therapy to help the 66% of patients still seeking relief from symptoms of PTSD.
Early clinical trials show this noninvasive earbud can reduce symptoms with no significant side effects, earning The Phoenix® a Breakthrough Device Designation by the FDA.
Now is a great time to join our mission to improve countless lives, enable a happier, healthier future, and empower patients.
Remember to share this opportunity with your network!
Warmly,
Weaver Gaines
CEO
Evren Technologies
“This testimonial may not be representative of the experience of other customers and is not a guarantee of future performance or success.”
Don’t miss your last chance to ask your investor questions directly to the CEO of Evren himself, Weaver Gaines. This will be his final webinar before Evren’s StartEngine campaign comes to a close.
Register today for our live webinar on August 16th at 4:00pm EDT to reserve your spot.
Evren’s Phoenix earbud provides personalized levels of vagal nerve stimulation to significantly reduce symptoms of PTSD while improving quality of life - without harmful side effects.
Learn how you can get in on the ground floor of this revolutionary technology.
We invite you to share our webinar with your friends, family, and network.
Warmly,
Weaver Gaines
CEO
Evren Technologies
Hello Evren Community!
Join CEO Weaver Gaines and the Evren Team for a final webinar before our StartEngine campaign ends.
Have all your questions about PTSD, vagus nerve stimulation therapy, and investment opportunities answered!
Register today for our live webinar on August 16th at 4:00 pm EDT!
Don’t miss out! This is your last chance to talk to Evren Technologies’s CEO Weaver Gaines live before our campaign comes to a close.
Visit our raise page to learn how you can be part of this exciting technology.
Help make a difference by sharing Evren’s mission with your family, friends, and network.
Warmly,
Weaver Gaines
CEO
Evren Technologies
{{ profileCtrl.commentsLoading ? 'Loading...' : 'Show More Comments' }}